Alberta Investment Management Corp Has $6.41 Million Stock Holdings in McKesson Corporation $MCK

Alberta Investment Management Corp raised its position in McKesson Corporation (NYSE:MCK) by 18.6% during the 3rd quarter, according to its most recent filing with the SEC. The institutional investor owned 8,300 shares of the company’s stock after acquiring an additional 1,300 shares during the period. Alberta Investment Management Corp’s holdings in McKesson were worth $6,412,000 as of its most recent filing with the SEC.

Other hedge funds also recently made changes to their positions in the company. Norges Bank bought a new position in McKesson in the second quarter valued at $1,346,661,000. Alliancebernstein L.P. boosted its stake in shares of McKesson by 150.4% during the 2nd quarter. Alliancebernstein L.P. now owns 2,268,015 shares of the company’s stock worth $1,661,956,000 after buying an additional 1,362,386 shares during the last quarter. Arrowstreet Capital Limited Partnership grew its holdings in shares of McKesson by 56.4% in the 2nd quarter. Arrowstreet Capital Limited Partnership now owns 1,236,536 shares of the company’s stock valued at $906,109,000 after acquiring an additional 446,060 shares in the last quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main increased its position in shares of McKesson by 45.6% in the second quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 833,780 shares of the company’s stock valued at $610,977,000 after acquiring an additional 261,296 shares during the last quarter. Finally, Acadian Asset Management LLC increased its position in shares of McKesson by 68.0% in the second quarter. Acadian Asset Management LLC now owns 636,596 shares of the company’s stock valued at $466,441,000 after acquiring an additional 257,670 shares during the last quarter. 85.07% of the stock is owned by institutional investors.

Insider Activity at McKesson

In other news, EVP Leann B. Smith sold 190 shares of the business’s stock in a transaction dated Tuesday, February 17th. The shares were sold at an average price of $945.00, for a total value of $179,550.00. Following the completion of the sale, the executive vice president owned 2,989 shares of the company’s stock, valued at approximately $2,824,605. The trade was a 5.98% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Thomas L. Rodgers sold 276 shares of the firm’s stock in a transaction dated Monday, January 5th. The stock was sold at an average price of $816.18, for a total transaction of $225,265.68. Following the transaction, the executive vice president directly owned 2,268 shares in the company, valued at approximately $1,851,096.24. This represents a 10.85% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 794 shares of company stock worth $718,056 in the last ninety days. 0.08% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

Several brokerages recently commented on MCK. Zacks Research cut McKesson from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, November 25th. Morgan Stanley reiterated an “overweight” rating and set a $966.00 price objective on shares of McKesson in a research note on Thursday, January 29th. Wall Street Zen cut shares of McKesson from a “buy” rating to a “hold” rating in a research note on Saturday, November 8th. Mizuho upped their price target on shares of McKesson from $880.00 to $885.00 and gave the stock a “neutral” rating in a research report on Thursday, February 5th. Finally, Barclays increased their price target on shares of McKesson from $960.00 to $1,050.00 and gave the company an “overweight” rating in a research note on Wednesday. Thirteen equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $943.50.

McKesson Stock Performance

NYSE MCK opened at $946.52 on Thursday. The stock has a market cap of $115.94 billion, a PE ratio of 27.22, a P/E/G ratio of 1.52 and a beta of 0.40. The firm has a 50-day moving average of $848.54 and a 200-day moving average of $793.10. McKesson Corporation has a 52-week low of $594.34 and a 52-week high of $971.93.

McKesson (NYSE:MCK) last announced its quarterly earnings results on Wednesday, February 4th. The company reported $9.34 EPS for the quarter, beating analysts’ consensus estimates of $9.19 by $0.15. The business had revenue of $106.16 billion for the quarter, compared to analyst estimates of $105.98 billion. McKesson had a net margin of 1.09% and a negative return on equity of 338.97%. McKesson’s quarterly revenue was up 11.4% on a year-over-year basis. During the same quarter in the prior year, the business earned $8.03 EPS. McKesson has set its FY 2026 guidance at 38.800-39.200 EPS. As a group, analysts predict that McKesson Corporation will post 32.77 EPS for the current fiscal year.

McKesson Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Wednesday, April 1st. Investors of record on Monday, March 2nd will be issued a dividend of $0.82 per share. This represents a $3.28 annualized dividend and a yield of 0.3%. The ex-dividend date of this dividend is Monday, March 2nd. McKesson’s dividend payout ratio (DPR) is presently 9.43%.

About McKesson

McKesson Corporation (NYSE: MCK) is a global healthcare services and distribution company that supplies pharmaceuticals, medical-surgical products and health care technology solutions. Founded in 1833 and headquartered in Irving, Texas, McKesson operates across the drug distribution and healthcare services value chain, connecting manufacturers, pharmacies, hospitals and health systems to help manage the movement of medicines and clinical supplies.

The company’s core activities include pharmaceutical wholesale distribution and logistics, specialty pharmacy services, and the provision of medical-surgical supplies to acute and non-acute care providers.